Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Li Lv,1 Yonghui Shi,1,2 Junyan Wu,1 Guocheng Li1,3 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, People’s Republic of China; 2Department of Pharmacy, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, 5113...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lv L, Shi Y, Wu J, Li G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer stem cells nanosized drug delivery systems bcscs nddss surface markers signaling pathway target Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9e84bc0e648e4f53a9cd37c112fb0644
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e84bc0e648e4f53a9cd37c112fb0644
record_format	dspace
spelling	oai:doaj.org-article:9e84bc0e648e4f53a9cd37c112fb06442021-12-02T13:43:49ZNanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting1178-2013https://doaj.org/article/9e84bc0e648e4f53a9cd37c112fb06442021-02-01T00:00:00Zhttps://www.dovepress.com/nanosized-drug-delivery-systems-for-breast-cancer-stem-cell-targeting-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Li Lv,1 Yonghui Shi,1,2 Junyan Wu,1 Guocheng Li1,3 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, People’s Republic of China; 2Department of Pharmacy, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, 511300, Guangdong, People’s Republic of China; 3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, People’s Republic of ChinaCorrespondence: Junyan Wu; Guocheng LiDepartment of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, 510120, Guangdong, People’s Republic of ChinaTel/Fax +86 20-81332367; +86 20-81332451Email wujunyan@mail.sysu.edu.cn; liguoch@mail.sysu.edu.cnAbstract: Breast cancer stem cells (BCSCs), also known as breast cancer initiating cells, are reported to be responsible for the initiation, progression, therapeutic resistance, and relapse of breast cancer. Conventional therapeutic agents mainly kill the bulk of breast tumor cells and fail to eliminate BCSCs, even enhancing the fraction of BCSCs in breast tumors sometimes. Therefore, it is essential to develop specific and effective methods of eliminating BCSCs that will enhance the efficacy of killing breast tumor cells and thereby, increase the survival rates and quality of life of breast cancer patients. Despite the availability of an increasing number of anti-BCSC agents, their clinical translations are hindered by many issues, such as instability, low bioavailability, and off-target effects. Nanosized drug delivery systems (NDDSs) have the potential to overcome the drawbacks of anti-BCSC agents by providing site-specific delivery and enhancing of the stability and bioavailability of the delivered agents. In this review, we first briefly introduce the strategies and agents used against BCSCs and then highlight the mechanism of action and therapeutic efficacy of several state-of-the-art NDDSs that can be used to treat breast cancer by eliminating BCSCs.Keywords: breast cancer stem cells, nanosized drug delivery systems, BCSCs, NDDSs, surface markers, signaling pathway, targetLv LShi YWu JLi GDove Medical Pressarticlebreast cancer stem cellsnanosized drug delivery systemsbcscsnddsssurface markerssignaling pathwaytargetMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1487-1508 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer stem cells nanosized drug delivery systems bcscs nddss surface markers signaling pathway target Medicine (General) R5-920
spellingShingle	breast cancer stem cells nanosized drug delivery systems bcscs nddss surface markers signaling pathway target Medicine (General) R5-920 Lv L Shi Y Wu J Li G Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
description	Li Lv,1 Yonghui Shi,1,2 Junyan Wu,1 Guocheng Li1,3 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, People’s Republic of China; 2Department of Pharmacy, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, 511300, Guangdong, People’s Republic of China; 3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, People’s Republic of ChinaCorrespondence: Junyan Wu; Guocheng LiDepartment of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, 510120, Guangdong, People’s Republic of ChinaTel/Fax +86 20-81332367; +86 20-81332451Email wujunyan@mail.sysu.edu.cn; liguoch@mail.sysu.edu.cnAbstract: Breast cancer stem cells (BCSCs), also known as breast cancer initiating cells, are reported to be responsible for the initiation, progression, therapeutic resistance, and relapse of breast cancer. Conventional therapeutic agents mainly kill the bulk of breast tumor cells and fail to eliminate BCSCs, even enhancing the fraction of BCSCs in breast tumors sometimes. Therefore, it is essential to develop specific and effective methods of eliminating BCSCs that will enhance the efficacy of killing breast tumor cells and thereby, increase the survival rates and quality of life of breast cancer patients. Despite the availability of an increasing number of anti-BCSC agents, their clinical translations are hindered by many issues, such as instability, low bioavailability, and off-target effects. Nanosized drug delivery systems (NDDSs) have the potential to overcome the drawbacks of anti-BCSC agents by providing site-specific delivery and enhancing of the stability and bioavailability of the delivered agents. In this review, we first briefly introduce the strategies and agents used against BCSCs and then highlight the mechanism of action and therapeutic efficacy of several state-of-the-art NDDSs that can be used to treat breast cancer by eliminating BCSCs.Keywords: breast cancer stem cells, nanosized drug delivery systems, BCSCs, NDDSs, surface markers, signaling pathway, target
format	article
author	Lv L Shi Y Wu J Li G
author_facet	Lv L Shi Y Wu J Li G
author_sort	Lv L
title	Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
title_short	Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
title_full	Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
title_fullStr	Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
title_full_unstemmed	Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting
title_sort	nanosized drug delivery systems for breast cancer stem cell targeting
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/9e84bc0e648e4f53a9cd37c112fb0644
work_keys_str_mv	AT lvl nanosizeddrugdeliverysystemsforbreastcancerstemcelltargeting AT shiy nanosizeddrugdeliverysystemsforbreastcancerstemcelltargeting AT wuj nanosizeddrugdeliverysystemsforbreastcancerstemcelltargeting AT lig nanosizeddrugdeliverysystemsforbreastcancerstemcelltargeting
_version_	1718392571121631232

Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Ejemplares similares